慢性静脉功能不全相关淋巴水肿的临床和经济影响以及静脉干预后持续水肿的发生率。

Phlebology Pub Date : 2024-06-01 Epub Date: 2024-02-12 DOI:10.1177/02683555241233355
Matthew Genet, Nicos Labropoulos, Antonios Gasparis, Thomas O'Donnell, Kush Desai
{"title":"慢性静脉功能不全相关淋巴水肿的临床和经济影响以及静脉干预后持续水肿的发生率。","authors":"Matthew Genet, Nicos Labropoulos, Antonios Gasparis, Thomas O'Donnell, Kush Desai","doi":"10.1177/02683555241233355","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To determine the demographics, outcomes, and healthcare utilization of patients with chronic venous insufficiency-associated lymphedema (CVI-LED) and the prevalence of lymphedema-specific therapy use after venous intervention.</p><p><strong>Methods: </strong>The IBM MarketScan Commercial and Medicare Claims Databases were examined for patients with CVI-LED. Patient demographics and the use of lymphedema-specific therapy before and after venous intervention were collected.</p><p><strong>Results: </strong>Of 85,601 LED patients identified, 8,406 also had a diagnosis of CVI. In the CVI-LED group, 1051 underwent endovenous ablation or venous stent placement. The use of lymphedema-specific therapy before and after venous intervention was 52% and 39%, respectively (<i>p</i> < .05). The mean time of initiation of LED-specific therapy following venous intervention was 265 days after ablation and 347 days after stent placement.</p><p><strong>Conclusion: </strong>Treating venous hypertension improves certain venous-related signs and symptoms of CVI. However, a significant proportion of patients have persistent edema which may reflect underlying, sub-optimally treated LED.</p>","PeriodicalId":94350,"journal":{"name":"Phlebology","volume":" ","pages":"353-358"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The clinical and economic impact of chronic venous insufficiency-associated lymphedema and the prevalence of persistent edema after venous intervention.\",\"authors\":\"Matthew Genet, Nicos Labropoulos, Antonios Gasparis, Thomas O'Donnell, Kush Desai\",\"doi\":\"10.1177/02683555241233355\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To determine the demographics, outcomes, and healthcare utilization of patients with chronic venous insufficiency-associated lymphedema (CVI-LED) and the prevalence of lymphedema-specific therapy use after venous intervention.</p><p><strong>Methods: </strong>The IBM MarketScan Commercial and Medicare Claims Databases were examined for patients with CVI-LED. Patient demographics and the use of lymphedema-specific therapy before and after venous intervention were collected.</p><p><strong>Results: </strong>Of 85,601 LED patients identified, 8,406 also had a diagnosis of CVI. In the CVI-LED group, 1051 underwent endovenous ablation or venous stent placement. The use of lymphedema-specific therapy before and after venous intervention was 52% and 39%, respectively (<i>p</i> < .05). The mean time of initiation of LED-specific therapy following venous intervention was 265 days after ablation and 347 days after stent placement.</p><p><strong>Conclusion: </strong>Treating venous hypertension improves certain venous-related signs and symptoms of CVI. However, a significant proportion of patients have persistent edema which may reflect underlying, sub-optimally treated LED.</p>\",\"PeriodicalId\":94350,\"journal\":{\"name\":\"Phlebology\",\"volume\":\" \",\"pages\":\"353-358\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phlebology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/02683555241233355\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02683555241233355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的确定慢性静脉功能不全相关淋巴水肿(CVI-LED)患者的人口统计学特征、治疗效果和医疗保健利用率,以及静脉干预后使用淋巴水肿特异性疗法的流行率:对 IBM MarketScan 商业和医疗保险索赔数据库中的 CVI-LED 患者进行了研究。方法:对 IBM MarketScan 商业数据库和医疗保险索赔数据库中的 CVI-LED 患者进行检查,收集患者的人口统计数据以及静脉干预前后淋巴水肿特异性疗法的使用情况:结果:在确定的 85,601 名 LED 患者中,有 8,406 人同时被诊断为 CVI。在 CVI-LED 组中,有 1051 人接受了静脉腔内消融术或静脉支架置入术。静脉介入治疗前后使用淋巴水肿特异性疗法的比例分别为 52% 和 39%(P < .05)。静脉介入治疗后开始使用淋巴水肿特异性疗法的平均时间为消融术后265天,支架置入术后347天:结论:治疗静脉高压可改善 CVI 某些与静脉相关的体征和症状。结论:治疗静脉高血压可改善某些与静脉相关的症状和体征,但相当一部分患者会出现持续性水肿,这可能反映了潜在的、未得到最佳治疗的 LED。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The clinical and economic impact of chronic venous insufficiency-associated lymphedema and the prevalence of persistent edema after venous intervention.

Objectives: To determine the demographics, outcomes, and healthcare utilization of patients with chronic venous insufficiency-associated lymphedema (CVI-LED) and the prevalence of lymphedema-specific therapy use after venous intervention.

Methods: The IBM MarketScan Commercial and Medicare Claims Databases were examined for patients with CVI-LED. Patient demographics and the use of lymphedema-specific therapy before and after venous intervention were collected.

Results: Of 85,601 LED patients identified, 8,406 also had a diagnosis of CVI. In the CVI-LED group, 1051 underwent endovenous ablation or venous stent placement. The use of lymphedema-specific therapy before and after venous intervention was 52% and 39%, respectively (p < .05). The mean time of initiation of LED-specific therapy following venous intervention was 265 days after ablation and 347 days after stent placement.

Conclusion: Treating venous hypertension improves certain venous-related signs and symptoms of CVI. However, a significant proportion of patients have persistent edema which may reflect underlying, sub-optimally treated LED.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Beyond water: 3D laser scanning offers a cutting-edge alternative for upper limb volume assessment. Eight year results of patients with varicose vein underwent endovenous occlusion using n-butyl cyanoacrylate. A systematic review and meta-analysis assessing the impact of pentoxifylline on the healing and recurrence of venous leg ulcers. Selected phlebological abstracts. Early experience managing intravascular coagulum using polidocanol endovenous microfoam: Risk factor analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1